Market Overview

Institute for Next Generation Healthcare (INGH) at the Icahn School of Medicine at Mount Sinai Announces Upcoming LymeMIND Conference on Lyme Disease and Precision Medicine

Share:

NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- The Institute for Next Generation Healthcare (INGH) at the Icahn School of Medicine at Mount Sinai today announced that it will be hosting its third annual LymeMIND conference on Tuesday, October 2, at the New York Academy of Medicine, and Wednesday, October 3, at the New York Academy of Science in New York, New York. The conference is designed to enhance the network of understanding among clinicians and researchers on the front lines of Lyme disease and the patients who have it.

Bringing together the collective community of partners dedicated to the fight against Lyme disease, INGH has assembled clinicians, researchers, patients, advocates, and innovators who will showcase some the latest research and clinical advancements in Lyme disease during the two-day conference. The discussions on October 2 will focus on the use of new next-generation technologies for both treatment and diagnostics, including current discovery and data collection efforts.  Speakers and panel discussions on October 3 will focus on providing patients with a greater sense of clarity on where current research stands and how the entire community can aid research efforts by becoming actively involved as citizen-scientists.

Speakers include leading physicians and academics in Lyme disease research alongside prominent Lyme disease patient advocates who understand the challenges individuals and their families face when coping with the disease. Key individuals and panelists include:

  • Joel Dudley, PhD, Director, Institute for Next Generation Healthcare at Mount Sinai
  • Richard I. Horowitz, MD, Medical Director, Hudson Valley Healing Arts Center
  • Monica E. Embers, PhD, Assistant Professor, Tulane University
  • Dana Parish, Author, Sony Music Artist, Lyme Educator
  • Suruchi Chandra, MD, Director, Integrative Psychiatry and Medicine
  • Nicole Baumgarth, PhD, Professor, University of California, Davis
  • Ying Zhang, MD, PhD, Professor, Johns Hopkins
  • John Aucott, MD, Director, Johns Hopkins Lyme Disease Clinical Research Center
  • Brian A. Fallon, MD, Director, Lyme & Tick-Borne Diseases Research Center
  • Savi Glowe, Director of Operations, Institute for Next Generation Healthcare

"To better treat this disease, it's of critical importance for researchers to fully consider both the short- and long-term impact on the patient.  However, this understanding has been hindered by a disconnect between researchers and the patient experience, as well as a lack of comprehensively analyzed data on the disease, its treatment and potential long-term effects of both," said Dr. Dudley. "The traditional hypothesis-guided approach has made it difficult for researchers to grasp the full complexity of Lyme, and therefore we haven't been able to rapidly advance treatment options and provide the greater Lyme community with a solution to mitigate and end suffering."

Dr. Dudley continued: "At the conference, we will not only share insight on next-generation technologies for clinicians and researchers to collect larger amounts of data at the molecular level, we will also provide our fully immersive interview booth to collect and share the human experience of Lyme disease so that, as a community, we can all better understand the impact of this complex illness. Through these discussions and innovations in technology, we hope to provide the spark needed to illuminate and eliminate this commonly overlooked disease."

The event is free and registration is necessary to attend. To learn more about the LymeMIND conference or to register, please visit www.LymeMIND.org

About the Institute for Next Generation Healthcare
The Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai is a new model of research, innovation, and market delivery founded in 2016 to expedite and help shape the impending revolution in health care. INGH is committed to building a new model of healthcare innovation and delivery by transforming our definition of "health" and accelerating new discoveries, technologies, and platforms to make the future of medicine a reality today. Positioned at the nexus of rapid advances in diagnostics technologies, digital health tools, and artificial intelligence, INGH aims to better use technology to empower patients, improve care, support physicians, and move away from the traditional model of health care as "sick care." Our broad, interdisciplinary view of health is grounded in the belief that patient engagement and behavior change are central to the mission of health optimization. Our objective is to intervene upstream from disease, developing predictive, diagnostic, and therapeutic technologies that move us from reactive to proactive medicine.

Media Relations Contact:
Kate Caruso-Sharpe
FischTank Marketing & PR
Kate@fischtankpr.com
646-699-1534

INGH_Logo_Color.jpg

View Comments and Join the Discussion!